ONCALIS AG
Oncalis AG operates as a biotech company that focused on the discovery and development of small molecule kinase inhibitors for oncology indications using its proprietary yeast-cell based, high-throughput screening platform for receptor tyrosine kinases.
ONCALIS AG
Industry:
Biotechnology Health Care Pharmaceutical
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Status:
Active
Contact:
+41 44 733 49 00
Similar Organizations
Kallistem
Kallistem is a biotech company
More informations about "Oncalis AG"
Oncalis AG - Crunchbase Company Profile & Funding
Oncalis AG operates as a biotech company that focused on the discovery and development of small molecule kinase inhibitors for oncology indications using its proprietary yeast-cell based, …See details»
Oncalis AG - Schlieren, Switzerland - bionity.com
Oncalis AG is a drug development company based in Schlieren near Zurich, Switzerland, focused on the development of orally available kinase inhibitors for the treatment of cancer. Kinase …See details»
Oncalis - VentureRadar
Oncalis AG is a spin-off from ESBATech AG, a biotechnology company that has developed technology platforms in both the antibody and small molecule areas of pharmaceutical …See details»
Oncalis AG - Company Profile and News - Bloomberg Markets
Company profile page for Oncalis AG including stock price, company news, executives, board members, and contact informationSee details»
Oncalis AG Company Profile, Financial and Strategic SWOT
Oncalis AG engages in the discovery and development of small molecule inhibitors for oncology indications. The company was founded in 2006 and is based in Schlieren, Switzerland. …See details»
Oncalis AG:Company Profile & Technical Research,Competitor …
Oncalis AG is headquartered in Switzerland ZURICH. Oncalis AG was founded in 2006. Oncalis AG has a total of 32 patents . Related Topics. Tyrosine High-throughput screening Kinase …See details»
Oncalis AG, Zug, Switzerland ︎ - North Data
Oncalis AG, Zug, Switzerland, Schweizer Handelsregister CHE-113.001.937: Network, Financial informationSee details»
Oncalis AG Licenses PI3K Inhibitors From ChemDiv, Inc.
Oct 6, 2008 Oncalis AG is a drug development company based in Schlieren near Zurich, Switzerland supported by VI Partners, Zurcher KantonalBank and private investors. Oncalis …See details»
Oncalis AG in Liquidation :: Switzerland :: OpenCorporates
Free and open company data on Switzerland company Oncalis AG in Liquidation (company number 841672), c/o VI Partners AG, Baarerstrasse, 86, Zug, 6302See details»
Oncalis AG - Drug pipelines, Patents, Clinical trials - Synapse
May 8, 2025 100 Translational Medicine associated with Oncalis AG. Login to view more data. Corporation Tree. Boost your research with our corporation tree data. login. or. view full …See details»
Oncalis | VentureRadar
Oncalis AG is a spin-off from ESBATech AG, a biotechnology company that has developed technology platforms in both the antibody and small molecule areas of pharmaceutical …See details»
Research programme: phosphatidylinositol 3-kinase inhibitors
Oncalis and ChemDiv are collaborating on the development of phosphatidylinositol 3-kinase (PI3-K) inhibitors for the treatment of cancer. A lead compound inSee details»
Oncalis AG Revonect Business Profile
Oncalis AG is a Biotechnology company located in 21 Wagistrasse, Schlieren, ZH, Switzerland. Biotechnology and Molecular Biology Research Companies in the biotechnology and …See details»
ESBATech Spins Out Oncalis For Oncology Drug Discovery
Sep 13, 2006 BioWorld International Correspondent. One month after closing a $41 million Series B round, ESBATech AG spun out a new company, Oncalis AG, to take charge of its …See details»
Oncalis AG Licenses PI3K Inhibitors From ChemDiv Inc.
Oct 6, 2008 Oncalis AG Licenses PI3K Inhibitors From ChemDiv Inc. SCHLIEREN, Switzerland, LAUSANNE, Switzerland and SAN DIEGO, Oct. 6 /PRNewswire/ -- Oncalis AG (Oncalis), a …See details»
Oncalis AG | Qodeo
View this profile now on qodeo. Valuation Valuations NowSee details»
Oncalis AG, Zug, Schweiz - North Data
Oncalis AG, Zug, Schweiz, Schweizer Handelsregister CHE-113.001.937: Netzwerk, WirtschaftsinfosSee details»
Research programme: receptor tyrosine kinase inhibitors
Oncalis, a spin-out company of ESBATech, is collaborating with ChemDiv to develop small molecule compounds targeting receptor tyrosine kinases, for theSee details»
Hans-Georg Capraro - Basel, Basel, Switzerland - LinkedIn
Independent Pharmaceuticals Professional · Experience: Oncalis AG, Schlieren · Education: National Inst. of Healths · Location: Basel · 87 connections on LinkedIn. View Hans-Georg …See details»
Oncalis AG Licenses PI3K Inhibitors From ChemDiv Inc.
SCHLIEREN, Switzerland, LAUSANNE, Switzerland and SAN DIEGO, October 6 /PRNewswire/ --Oncalis AG (Oncalis), a privately-owned Swiss biotechnology company, and ChemDiv Inc. …See details»